Skip to main content Accessibility help
×
Home

Efficacy and safety of idalopirdine for Alzheimer’s disease: a systematic review and meta-analysis

  • Shinji Matsunaga (a1), Hiroshige Fujishiro (a2) and Hajime Takechi (a1)

Abstract

Objective:

The efficacy and tolerability of idalopirdine, a selective 5-hydroxytryptamine6 receptor antagonist, in patients with Alzheimer’s disease (AD) is uncertain. A systematic review and meta-analysis of randomized controlled trials (RCTs) testing idalopirdine for patients with AD was performed.

Methods:

We included RCTs of idalopirdine for patients with AD and used Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) scores as a primary measure.

Results:

Four RCTs with 2,803 patients with AD were included. There was no significant difference in ADAS-cog between the idalopirdine and placebo groups [mean difference (MD) = −0.41, P = 0.32, I2 = 62%]. However, significant heterogeneity remained. Sensitivity analysis revealed that idalopirdine was more effective than placebo for ADAS-cog in the high dose and moderate AD subgroups (high dose subgroup: MD = −2.15, P = 0.005, moderate AD subgroup: MD = −2.15, P = 0.005). Moreover, meta-regression analysis showed that idalopirdine effect size for ADAS-cog was associated with mean dose (coefficient, −0.0289), ADAS-cog at baseline (coefficient, −0.9519), and proportion of male participants (coefficient, 0.2214). For safety outcomes, idalopirdine was associated with a higher incidence of at least one adverse event and increased γ-glutamyltransferase, alanine aminotransferase, aspartate aminotransferase, and vomiting than placebo. There were no significant differences in other secondary outcomes between both treatments.

Conclusions:

Idalopirdine is not effective for AD patients and is associated with a risk of elevated liver enzymes and vomiting. Although idalopirdine might be more effective at high doses and in moderate AD subgroups, the effect size is small and may be limited.

Copyright

Corresponding author

Correspondence should be addressed to: Shinji Matsunaga, Department of Geriatrics and Cognitive Disorders, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, 470-1192 Toyoake, Aichi, Japan. Phone: +81-562-93-9083; Fax: +81-562-93-9021. Email: shinjim@fujita-hu.ac.jp.

References

Hide All
Atri, A. et al. (2018). Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: three randomized clinical trials. JAMA, 319, 130142. doi: 10.1001/jama.2017.
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A. and Gornbein, J. (1994). The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology, 44, 23082314. doi: 10.1212/WNL.44.12.
Dyer, S. M., Harrison, S. L., Laver, K., Whitehead, C. and Crotty, M. (2018). An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia. International Psychogeriatrics, 30, 295309.
Erkkinen, M. G., Kim, M. O. and Geschwind, M. D. (2018). Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harbor Perspectives in Biology, 2, 10. doi: 10.1101/cshperspect.a033118.
Ferrero, H., Solas, M., Francis, P. T. and Ramirez, M. J. (2017). Serotonin 5-HT6 receptor antagonists in Alzheimer’s disease: therapeutic rationale and current development status. CNS Drugs, 31, 1932. doi: 10.1007/s40263-016-0399-3.
Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975). “Mini-Mental State.” A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189198. doi: 10.1016/0022-3956(75)90026-6.
Galasko, D. et al. (1997). An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Disease and Associated Disorders, 11, S3339. doi: 10.1097/00002093-199700112-00005.
Higgins, J. P., Thompson, S. G., Deeks, J. J. and Altman, D. G. (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557560. doi: 10.1136/bmj.327.7414.557.
Hurst, N. P., Kind, P., Ruta, D., Hunter, M. and Stubbings, A. (1997). Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). British Journal of Rheumatology, 36, 551559. doi: 10.1093/rheumatology/36.5.551.
Khoury, R., Grysman, N., Gold, J., Patel, K. and Grossberg, G. T. (2018). The role of 5 HT6-receptor antagonists in Alzheimer’s disease: an update. Expert Opinion on Investigational Drugs, 27, 523533. doi: 10.1080/13543784.2018.1483334.
Lorke, D. E., Lu, G., Cho, E. and Yew, D. T. (2006). Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neuroscience, 7, 36. doi: 10.1186/1471-2202-7-36.
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B. and Bero, L. (2017). Industry sponsorship and research outcome. Cochrane Database Systems Review, 2, MR000033.
Maher-Edwards, G. et al. (2010). Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer’s disease. Current Alzheimer Research, 7, 374385. doi: 10.2174/156720510791383831.
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. and Group, P. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, b2535. doi: 10.1136/bmj.b2535.
Ramirez, M. J. (2013). 5-HT6 receptors and Alzheimer’s disease. Alzheimers Research & Therapy, 5, 15.
Rosen, W. G., Mohs, R. C. and Davis, K. L. (1984). A new rating scale for Alzheimer’s disease. The American Journal of Psychiatry, 141, 13561364. doi: 10.1176/ajp.141.11.1356.
Scheltens, P. et al. (2016). Alzheimer’s disease. Lancet, 388, 505517. doi: 10.1016/S0140-6736(15)01124-1.
Schneider, L. S. et al. (2006). ADCS Prevention Instrument Project: ADCS-clinicians’ global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions. Alzheimer Disease & Associated Disorders, 20, S124138.
Tricco, A. C. et al. (2018). Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer’s disease: systematic review and network meta analysis. Journal of the American Geriatrics Society, 66, 170178. doi: 10.1111/jgs.15069.
Wilkinson, D., Windfeld, K. and Colding-Jorgensen, E. (2014). Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer’s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Neurology, 13, 10921099. doi: 10.1016/S1474-4422(14)70198-X.
Winblad, B. et al. (2016). Defeating Alzheimer’s disease and other dementias: a priority for European science and society. The Lancet Neurology, 15, 455532. doi: 10.1016/S1474-4422(16)00062-4.

Keywords

Type Description Title
WORD
Supplementary materials

Matsunaga et al. supplementary material
Appendices S1-S5

 Word (640 KB)
640 KB

Efficacy and safety of idalopirdine for Alzheimer’s disease: a systematic review and meta-analysis

  • Shinji Matsunaga (a1), Hiroshige Fujishiro (a2) and Hajime Takechi (a1)

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed